Agilent Technologies has completed its acquisition of Proscia for $240 million upfront, adding digital-pathology software and AI-enabled diagnostic capabilities to its life sciences and diagnostics business.

ANI Pharmaceuticals has launched a recommended cash offer valued at approximately $560 million for Swedish rare-disease specialist Egetis Therapeutics, seeking to add the approved MCT8-deficiency treatment Emcitate to its portfolio.

India's HRV Pharma has acquired Germany-based Phatebo GmbH, establishing a European platform for finished-dose pharmaceuticals and clinical-trial supply services beyond its existing active pharmaceutical ingredients business.

Lonza has agreed to acquire five US contract development and manufacturing facilities from Merck KGaA, strengthening its capabilities in advanced biologics, bioconjugation, viral vectors and specialised drug delivery.

Zydus Lifesciences has completed its acquisition of Sterling Biotech's fermentation-based active pharmaceutical ingredients business, expanding its manufacturing capabilities in India.

Teva has acquired worldwide rights to BioXcel's BXCL501 neuroscience programme and approved IGALMI product in an asset transaction worth up to $125 million.

Aptar Pharma has acquired German inhalation technology specialist Pulmotree, adding its Kolibri platform to expand next-generation pulmonary drug delivery capabilities.